AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Publication | Open Access

DOI Full Paper Access

Citations

References

2022

Year

Lukas Bunse, Anne-Kathleen Rupp, Isabel Poschke, Theresa Bunse, Katharina A.M. Lindner, Antje Wick, Jens Blobner, Martin Misch, Ghazaleh Tabatabai, Martin Glas,

Neurological Research and Practice